Dhillon, A.

patient lamivudine interferon hbeag treatment hepatitis combination study seroconversion hbeag seroconversion rate monotherapy lamivudine monotherapy therapy hepatitis b combination therapy hbeag seroconversion week 52 group professor baseline population ymdd variant hbv hbv dna serum hbeag seroconversion rates combination treatment analysis hepatitis b infection trial lamivudine 100 mg 52 weeks glaxo wellcome event histological randomised hepatitis b virus infection 16 weeks interferon monotherapy lamivudine therapy level virus variant value liver article itt population incidence screening lamivudine treatment combination group schalm evect month point heathcote gut.bmj.com cianciara response evidence december asian patients glaxo downloaded wellcome result hepatology eycacy protocol centre gastroenterology medication score antigen disease hbv dna values protocol population limit baseline alt levels hospital